BALVERSA 5 mg/1
Erdafitinib · TABLET, FILM COATED · Janssen Products LP
Balversa (erdafitinib) is an oral kinase inhibitor tablet used to treat certain types of bladder cancer with specific fibroblast growth factor receptor mutations. It works by blocking proteins that help cancer cells grow and divide.
Key Facts
- Brand Name
- BALVERSA
- Generic Name
- Erdafitinib
- NDC Code (Product)
59676-050- Manufacturer
- Janssen Products LP
- Strength
- 5 mg/1
- Dosage Form
- TABLET, FILM COATED
- Route
- ORAL
- Marketing Status
- Application #
- NDA212018
- Drug Class
- Kinase Inhibitor [EPC]
- Marketing Start
- 04/12/2019
Recall History
No Recall HistoryFrequently Asked Questions
What is BALVERSA used for?
Balversa (erdafitinib) is an oral kinase inhibitor tablet used to treat certain types of bladder cancer with specific fibroblast growth factor receptor mutations. It works by blocking proteins that help cancer cells grow and divide.
Is BALVERSA a controlled substance?
BALVERSA is not classified as a controlled substance by the DEA.
What is the generic name for BALVERSA?
The generic name for BALVERSA is Erdafitinib. There are no other listed brand versions of Erdafitinib.
What is the NDC code for BALVERSA 5 mg/1?
The NDC (National Drug Code) for BALVERSA 5 mg/1 is 59676-050, listed by Janssen Products LP.
Other BALVERSA Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)